Fibrolamellar carcinoma: A histologically unique tumor with unique molecular findings

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Fibrolamellar carcinoma is a unique type of hepatocellular carcinoma with a distinctive predilection for young patients without underlying liver disease, characteristic large neoplastic cells with intervening, dense fibrosis, co-expression of keratin 7 and CD68 and activation of protein kinase A (most often by formation of DNAJB1-PRKACA). Fibrolamellar carcinoma has a similar prognosis to conventional hepatocellular carcinomas arising in non-cirrhotic livers. The current American Joint Cancer Committee staging system does not provide optimal stratification of patients with fibrolamellar carcinoma and an alternate systems should be considered in the future. The only effective treatment for fibrolamellar carcinoma is complete resection. Novel therapies may be on the horizon as investigation into the molecular biology of fibrolamellar carcinoma continues.

Original languageEnglish (US)
Pages (from-to)146-152
Number of pages7
JournalSeminars in Diagnostic Pathology
Volume34
Issue number2
DOIs
StatePublished - Mar 1 2017

Fingerprint

Carcinoma
Neoplasms
Hepatocellular Carcinoma
Keratin-7
Neoplasm Staging
Cyclic AMP-Dependent Protein Kinases
Liver Diseases
Molecular Biology
Fibrosis
Joints
Liver
Therapeutics

Keywords

  • Carney complex
  • Central scar
  • Cytokeratin 7
  • PRKACA rearrangements

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

@article{7214357e948f46bb9231e4364951b49c,
title = "Fibrolamellar carcinoma: A histologically unique tumor with unique molecular findings",
abstract = "Fibrolamellar carcinoma is a unique type of hepatocellular carcinoma with a distinctive predilection for young patients without underlying liver disease, characteristic large neoplastic cells with intervening, dense fibrosis, co-expression of keratin 7 and CD68 and activation of protein kinase A (most often by formation of DNAJB1-PRKACA). Fibrolamellar carcinoma has a similar prognosis to conventional hepatocellular carcinomas arising in non-cirrhotic livers. The current American Joint Cancer Committee staging system does not provide optimal stratification of patients with fibrolamellar carcinoma and an alternate systems should be considered in the future. The only effective treatment for fibrolamellar carcinoma is complete resection. Novel therapies may be on the horizon as investigation into the molecular biology of fibrolamellar carcinoma continues.",
keywords = "Carney complex, Central scar, Cytokeratin 7, PRKACA rearrangements",
author = "Rondell Graham and Michael Torbenson",
year = "2017",
month = "3",
day = "1",
doi = "10.1053/j.semdp.2016.12.010",
language = "English (US)",
volume = "34",
pages = "146--152",
journal = "Seminars in Diagnostic Pathology",
issn = "0740-2570",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Fibrolamellar carcinoma

T2 - A histologically unique tumor with unique molecular findings

AU - Graham, Rondell

AU - Torbenson, Michael

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Fibrolamellar carcinoma is a unique type of hepatocellular carcinoma with a distinctive predilection for young patients without underlying liver disease, characteristic large neoplastic cells with intervening, dense fibrosis, co-expression of keratin 7 and CD68 and activation of protein kinase A (most often by formation of DNAJB1-PRKACA). Fibrolamellar carcinoma has a similar prognosis to conventional hepatocellular carcinomas arising in non-cirrhotic livers. The current American Joint Cancer Committee staging system does not provide optimal stratification of patients with fibrolamellar carcinoma and an alternate systems should be considered in the future. The only effective treatment for fibrolamellar carcinoma is complete resection. Novel therapies may be on the horizon as investigation into the molecular biology of fibrolamellar carcinoma continues.

AB - Fibrolamellar carcinoma is a unique type of hepatocellular carcinoma with a distinctive predilection for young patients without underlying liver disease, characteristic large neoplastic cells with intervening, dense fibrosis, co-expression of keratin 7 and CD68 and activation of protein kinase A (most often by formation of DNAJB1-PRKACA). Fibrolamellar carcinoma has a similar prognosis to conventional hepatocellular carcinomas arising in non-cirrhotic livers. The current American Joint Cancer Committee staging system does not provide optimal stratification of patients with fibrolamellar carcinoma and an alternate systems should be considered in the future. The only effective treatment for fibrolamellar carcinoma is complete resection. Novel therapies may be on the horizon as investigation into the molecular biology of fibrolamellar carcinoma continues.

KW - Carney complex

KW - Central scar

KW - Cytokeratin 7

KW - PRKACA rearrangements

UR - http://www.scopus.com/inward/record.url?scp=85009756544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009756544&partnerID=8YFLogxK

U2 - 10.1053/j.semdp.2016.12.010

DO - 10.1053/j.semdp.2016.12.010

M3 - Article

C2 - 28110996

AN - SCOPUS:85009756544

VL - 34

SP - 146

EP - 152

JO - Seminars in Diagnostic Pathology

JF - Seminars in Diagnostic Pathology

SN - 0740-2570

IS - 2

ER -